# Kristopher W. Krausz

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/kristopher-w-krausz/

## Facts

| Field | Value |
| --- | --- |
| Citations | 18,970 |
| Field | Metabolomics and Mass Spectrometry Studies |
| h-index | 73 |
| i10-index | 199 |
| Last Known Institution | National Cancer Institute |
| OpenAlex ID | https://openalex.org/A5064080263 |
| ORCID iD | https://orcid.org/0000-0003-2910-7787 |
| Works | 370 |

## Researcher papers

- [Gut microbiota and intestinal FXR mediate the clinical benefits of metformin](https://scholariq.org/papers/gut-microbiota-and-intestinal-fxr-mediate-the-clinical-benefits-of-metformin/)
- [Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity](https://scholariq.org/papers/microbiome-remodelling-leads-to-inhibition-of-intestinal-farnesoid-x-receptor/)
- [Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease](https://scholariq.org/papers/intestinal-farnesoid-x-receptor-signaling-promotes-nonalcoholic-fatty-liver/)
- [Intermittent Fasting Promotes White Adipose Browning and Decreases Obesity by Shaping the Gut Microbiota](https://scholariq.org/papers/intermittent-fasting-promotes-white-adipose-browning-and-decreases-obesity-by/)
- [Intestine farnesoid X receptor agonist and the gut microbiota activate G‐protein bile acid receptor‐1 signaling to improve metabolism](https://scholariq.org/papers/intestine-farnesoid-x-receptor-agonist-and-the-gut-microbiota-activate-g-protein/)
- [Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction](https://scholariq.org/papers/intestine-selective-farnesoid-x-receptor-inhibition-improves-obesity-related/)
- [Bile salt hydrolase catalyses formation of amine-conjugated bile acids](https://scholariq.org/papers/bile-salt-hydrolase-catalyses-formation-of-amine-conjugated-bile-acids/)

## Researcher topics

- [Metabolomics and Mass Spectrometry Studies](https://scholariq.org/topics/metabolomics-and-mass-spectrometry-studies/)
- [Pharmacogenetics and Drug Metabolism](https://scholariq.org/topics/pharmacogenetics-and-drug-metabolism/)
- [Drug Transport and Resistance Mechanisms](https://scholariq.org/topics/drug-transport-and-resistance-mechanisms/)
- [Cancer, Hypoxia, and Metabolism](https://scholariq.org/topics/cancer-hypoxia-and-metabolism/)
- [Liver Disease Diagnosis and Treatment](https://scholariq.org/topics/liver-disease-diagnosis-and-treatment/)

## Researcher university

- [National Cancer Institute](https://scholariq.org/institutions/national-cancer-institute-3/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.